New CAR T-Cell trial offers hope for Tough-to-Treat blood cancers

NCT ID NCT03938987

First seen Feb 10, 2026 · Last updated May 18, 2026 · Updated 20 times

Summary

This study tests a personalized treatment using a patient's own immune cells, modified to attack cancer. It is for people with relapsed aggressive lymphoma or acute lymphoblastic leukemia (ALL) who have not responded to standard therapies. The approach aims to control the disease, but ongoing management may be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Alberta Children's Hospital

    NOT_YET_RECRUITING

    Calgary, Alberta, T3B6A8, Canada

    Contact

  • Cross Cancer Institute

    RECRUITING

    Edmonton, Alberta, T6G1Z2, Canada

    Contact

  • Foothills Medical Centre

    NOT_YET_RECRUITING

    Calgary, Alberta, T2N2T9, Canada

    Contact

  • Stollery Children's Hospital

    NOT_YET_RECRUITING

    Edmonton, Alberta, T6G2B7, Canada

    Contact

  • Tom Baker Cancer Centre

    NOT_YET_RECRUITING

    Calgary, Alberta, T2N4N2, Canada

    Contact

  • University of Alberta Hospital

    RECRUITING

    Edmonton, Alberta, T6G2B7, Canada

    Contact

Conditions

Explore the condition pages connected to this study.